Paper Titles

Study of the Protective Effect of Schizandra chinensis Polysaccharide on Oxidative Damage of Mouse Spermatozoa In Vitro
p.1973

The Application of Translational Medicine in Pharmacological Teaching
p.1978

Changes in the Quality of Soybean during Warehouse Storage
p.1982

An Experimental Study on the Rainfall-Runoff Progress of Wheat under Different Slope Angle
p.1986

Cognitive Behavior Therapy Ameliorates Non-Motor Symptoms in Parkinson's Disease
p.1995

Study on the Shelf Life Quality of Kiwifruit with Different Maturity
p.2006

Quantitative Analysis of Radix Rehmanniae from Genuine Producing Area by Near Infrared Spectroscopy
p.2010

The Study of Stability of Processing Grease Storage Temperature on Soybean
p.2014

Hardness of the Schizolobium amazonicum Wood
p.2018

HomeAdvanced Materials ResearchAdvanced Materials Research Vols. 912-914Cognitive Behavior Therapy Ameliorates Non-Motor...

Cognitive Behavior Therapy Ameliorates Non-Motor Symptoms in Parkinson's Disease

Article Preview

Abstract:

Non-motor symptoms (NMS) occur commonly in PD patients. The NMS is associated with the deterioration of life quality in Parkinsons disease (PD), even exceeding the effects of the motor disorder. To determine the effects of cognitive behavior therapy (CBT) on NMS in PD, fifty-five PD individuals with CBT intervention were matched for forty-eight control PD participants. NMS of all PD patients including depressive symptoms, sleep quality, cognitive function and physical and mental health-related quality of life were respectively assessed. Results indicate that CBT ameliorates NMS of PD patients, and that is significantly related with the decreases of serum inflammatory cytokines levels.

You might also be interested in these eBooks

Frontiers of Advanced Materials and Engineering Technology II

Info:

Periodical:

Advanced Materials Research (Volumes 912-914)

Pages:

1995-2005

DOI:

https://doi.org/10.4028/www.scientific.net/AMR.912-914.1995

Citation:

Cite this paper

Online since:

April 2014

Authors:

Chun Yan Wang*, Di Li, Shu Kun Yu, Ming Hong Wang, Qing Guan, Chun Hui Li

Keywords:

Cognitive Behavior Therapy, Inflammatory Cytokines , Mental Health-Related Quality of Life, Non-Motor Symptoms, Parkinson's Disease, Physical Health-Related Quality of Life

Export:

RIS, BibTeX

Price:

Permissions CCC:

Request Permissions

Permissions PLS:

Request Permissions

Сopyright:

© 2014 Trans Tech Publications Ltd. All Rights Reserved

Share:

Citation:

* - Corresponding Author

[1] Dauer W, Przedborski S: Parkinson's disease: mechanisms and models. Neuron 39 (2003): 889-909.

DOI: 10.1016/s0896-6273(03)00568-3

[2] Jacob EL, Gatto NM, Thompson A, Bordelon Y, Ritz B: Occurrence of depression and anxiety prior to Parkinson's disease. Parkinsonism Relat Disord 16 (2010): 576-581.

DOI: 10.1016/j.parkreldis.2010.06.014

[3] Cummings JL: Depression and Parkinson's disease: a review. Am J Psychiatry 149 (1992): 443-454.

[4] Richard IH, Frank S, McDermott MP, Wang H, Justus AW, et al: The ups and downs of Parkinson disease: a prospective study of mood and anxiety fluctuations. Cogn Behav Neurol 17 (2004): 201-207.

[5] Burn DJ: Depression in Parkinson's disease. Eur J Neurol 9 Suppl 3 (2002): 44-54.

[6] Starkstein SE, Mayberg HS, Leiguarda R, Preziosi TJ, Robinson RG: A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 55(1992): 377-382.

DOI: 10.1136/jnnp.55.5.377

[7] Pankratz N, Marder KS, Halter CA, Rudolph A, Shults CW, et al: Clinical correlates of depressive symptoms in familial Parkinson's disease. Mov Disord 23 (2008): 2216-2223.

DOI: 10.1002/mds.22285

[8] Dzirasa K, Ribeiro S, Costa R, Santos LM, Lin SC, et al: Dopaminergic control of sleep-wake states. J Neurosci 26 (2006): 10577-10589.

DOI: 10.1523/jneurosci.1767-06.2006

[9] Shaw PJ, Cirelli C, Greenspan RJ, Tononi G: Correlates of sleep and waking in Drosophila melanogaster. Science 287 (2000): 1834-1837.

DOI: 10.1126/science.287.5459.1834

[10] Cirelli C, Gutierrez CM, Tononi G: Extensive and divergent effects of sleep and wakefulness on brain gene expression. Neuron 41(2004): 35-43.

DOI: 10.1016/s0896-6273(03)00814-6

[11] Volkow ND, Wang GJ, Telang F, Fowler JS, Logan J, et al: Sleep deprivation decreases binding of [11C]raclopride to dopamine D2/D3 receptors in the human brain. J Neurosci 28 (2008): 8454-8461.

DOI: 10.1523/jneurosci.1443-08.2008

[12] Happe S, Ludemann P, Berger K: The association between disease severity and sleep-related problems in patients with Parkinson's disease. Neuropsychobiology 46 (2002): 90-96.

DOI: 10.1159/000065418

[13] Zoccolella S, Savarese M, Lamberti P, Manni R, Pacchetti C, et al: Sleep disorders and the natural history of Parkinson's disease: the contribution of epidemiological studies. Sleep Med Rev 15 (2011): 41-50.

DOI: 10.1016/j.smrv.2010.02.004

[14] Stavitsky K, Neargarder S, Bogdanova Y, McNamara P, Cronin-Golomb A: The impact of sleep quality on cognitive functioning in Parkinson's disease. J Int Neuropsychol Soc 18 (2012): 108-117.

DOI: 10.1017/s1355617711001482

[15] Ratcliff R, Van Dongen HP: Sleep deprivation affects multiple distinct cognitive processes. Psychon Bull Rev 16 (2009): 742-751.

DOI: 10.3758/pbr.16.4.742

[16] Dobkin RD, Allen LA, Menza M: A cognitive-behavioral treatment package for depression in Parkinson's disease. Psychosomatics 47(2006): 259-263.

DOI: 10.1176/appi.psy.47.3.259

[17] Beck AT: The current state of cognitive therapy: a 40-year retrospective. Arch Gen Psychiatry 62 (2005): 953-959.

DOI: 10.1001/archpsyc.62.9.953

[18] Dobkin RD, Allen LA, Menza M: Cognitive-behavioral therapy for depression in Parkinson's disease: a pilot study. Mov Disord 22 (2007): 946-952.

DOI: 10.1002/mds.21455

[19] Dobkin RD, Menza M, Allen LA, Gara MA, Mark MH, et al: Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial. Am J Psychiatry 168 (2011): 1066-1074.

DOI: 10.1176/appi.ajp.2011.10111669

[20] Gelb DJ, Oliver E, Gilman S: Diagnostic criteria for Parkinson disease. Arch Neurol 56(1999): 33-39.

DOI: 10.1001/archneur.56.1.33

[21] Marsh L, McDonald WM, Cummings J, Ravina B: Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group. Mov Disord 21 (2006): 148-158.

DOI: 10.1002/mds.20723

[22] Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 23 (1960): 56-62.

[23] Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ: The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28 (1989): 193-213.

DOI: 10.1016/0165-1781(89)90047-4

[24] Beevers CG, Strong DR, Meyer B, Pilkonis PA, Miller IR: Efficiently assessing negative cognition in depression: an item response theory analysis of the Dysfunctional Attitude Scale. Psychol Assess 19 (2007): 199-209.

DOI: 10.1037/1040-3590.19.2.199

[25] Tanaka N, Uji M, Hiramura H, Chen Z, Shikai N, et al: Cognitive patterns and depression: study of a Japanese university student population. Psychiatry Clin Neurosci 60 (2006): 358-364.

DOI: 10.1111/j.1440-1819.2006.01514.x

[26] Matsunaga M, Okamoto Y, Suzuki S, Kinoshita A, Yoshimura S, et al: Psychosocial functioning in patients with Treatment-Resistant Depression after group cognitive behavioral therapy. BMC Psychiatry 10 (2010): 22.

DOI: 10.1186/1471-244x-10-22

[27] Ware JE, Jr., Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30 (1992): 473-483.

DOI: 10.1097/00005650-199206000-00002

[28] Leger D, Scheuermaier K, Philip P, Paillard M, Guilleminault C: SF-36: evaluation of quality of life in severe and mild insomniacs compared with good sleepers. Psychosom Med 63 (2001): 49-55.

DOI: 10.1097/00006842-200101000-00006

[29] Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M: Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med 4 (2008): 487-504.

DOI: 10.5664/jcsm.27286

[30] Means MK, Lineberger MD, Edinger JD: Nonpharmacologic treatment of insomnia. Curr Treat Options Neurol 10 (2008): 342-349.

DOI: 10.1007/s11940-008-0037-6

[31] Van Houdenhove L, Buyse B, Gabriels L, Van den Bergh O: Treating primary insomnia: clinical effectiveness and predictors of outcomes on sleep, daytime function and health-related quality of life. J Clin Psychol Med Settings 18 (2011): 312-321.

DOI: 10.1007/s10880-011-9250-7

[32] Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek H, et al: Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 202 (1995): 17-20.

DOI: 10.1016/0304-3940(95)12192-7

[33] Scalzo P, Kummer A, Cardoso F, Teixeira AL: Serum levels of interleukin-6 are elevated in patients with Parkinson's disease and correlate with physical performance. Neurosci Lett 468 (2010): 56-58.

DOI: 10.1016/j.neulet.2009.10.062

[34] Ouchi Y, Yagi S, Yokokura M, Sakamoto M: Neuroinflammation in the living brain of Parkinson's disease. Parkinsonism Relat Disord 15 Suppl 3 (2009): S200-204.

DOI: 10.1016/s1353-8020(09)70814-4

[35] Brodacki B, Staszewski J, Toczylowska B, Kozlowska E, Drela N, et al: Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci Lett 441 (2008).

DOI: 10.1016/j.neulet.2008.06.040

[36] Bialecka M, Klodowska-Duda G, Kurzawski M, Slawek J, Gorzkowska A, et al: Interleukin-10 (IL10) and tumor necrosis factor alpha (TNF) gene polymorphisms in Parkinson's disease patients. Parkinsonism Relat Disord 14 (2008): 636-640.

DOI: 10.1016/j.parkreldis.2008.02.001